Dolutegravir

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2544 publications

Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV.

Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV.

Journal: eLife
Published: January 23, 2026

HIV expression persists in the cerebrospinal fluid of HIV-associated neurocognitive disorders despite effective ART.

HIV expression persists in the cerebrospinal fluid of HIV-associated neurocognitive disorders despite effective ART.

Journal: Emerging microbes & infections
Published: January 13, 2026

Prevalence of Adverse Drug Reactions among People Living with HIV in Lagos State University Teaching Hospital, Lagos, Nigeria.

Prevalence of Adverse Drug Reactions among People Living with HIV in Lagos State University Teaching Hospital, Lagos, Nigeria.

Journal: Nigerian medical journal : journal of the Nigeria Medical Association
Published: January 09, 2026

Dolutegravir concentrations in children receiving 3-month weekly isoniazid and rifapentine (3HP) for tuberculosis prevention.

Dolutegravir concentrations in children receiving 3-month weekly isoniazid and rifapentine (3HP) for tuberculosis prevention.

Journal: Microbiology spectrum
Published: January 08, 2026

Low Rates of Virological Failure and Acquired HIV-1 Drug Resistance Among Children in Cameroon: Evidence Following Transition to Dolutegravir-based Regimens in Pediatrics.

Low Rates of Virological Failure and Acquired HIV-1 Drug Resistance Among Children in Cameroon: Evidence Following Transition to Dolutegravir-based Regimens in Pediatrics.

Journal: The Pediatric infectious disease journal
Published: January 07, 2026

Protecting the Promise of Dolutegravir for Children living with HIV.

Protecting the Promise of Dolutegravir for Children living with HIV.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: January 01, 2026

HIV-associated drug-resistant TB: expanded treatment options and emerging threats.

HIV-associated drug-resistant TB: expanded treatment options and emerging threats.

Journal: Current opinion in HIV and AIDS
Published: December 29, 2025

Real-Life Long-Term Weight Trends After Switching to INSTI-Based Therapy in People Living with HIV: A 12-Year Retrospective Cohort Study.

Real-Life Long-Term Weight Trends After Switching to INSTI-Based Therapy in People Living with HIV: A 12-Year Retrospective Cohort Study.

Journal: The new microbiologica
Published: December 23, 2025

Basic Science and Pathogenesis.

Basic Science and Pathogenesis.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: December 23, 2025

Maternal and health worker preferences for paediatric antiretroviral formulations in neonates exposed to HIV.

Maternal and health worker preferences for paediatric antiretroviral formulations in neonates exposed to HIV.

Journal: AIDS care
Published: December 05, 2025

Dolutegravir-based therapy, diet, physical activity and weight gain: a 48-week prospective cohort in South Africa.

Dolutegravir-based therapy, diet, physical activity and weight gain: a 48-week prospective cohort in South Africa.

Journal: Journal of acquired immune deficiency syndromes (1999)
Published: December 02, 2025

Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update.

Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update.

Journal: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
Published: December 01, 2025
Showing 1-12 of 2,544

Last Updated: 02/24/2026